Drug Database
Back to search

Poland· PL-100469780

Argipressin Farmak

A vasopressin (argipressin) product containing argipressinum, registered in Poland by Farmak International Sp. z o.o.. The same ATC class is registered in 10 of our 19 countries.

ATC H01BA01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedArgipressin FarmakATCH01BA01REGISTER NO.PL-100469780PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about argipressinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Vasopressin (argipressin) is registered in 10 of 19 countries.

Countries holding a registration under ATC H01BA01 (vasopressin (argipressin)), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search vasopressin (argipressin) products by name

Vasopressin (argipressin) · ATC H01BA01

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Argipressinum
Manufacturer
Farmak International Sp. z o.o.
Country
Poland (PL)
ATC code
H01BA01
ATC class
Vasopressin (argipressin)
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05907637916146
  • gtin
    05907637916153

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

166 interactions on record for vasopressin (argipressin).

Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check vasopressin (argipressin) against other medicinesHow interaction checks work

Vasopressin (argipressin) · interactions on record

166 records

  • 39 severe
  • 125 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Vasopressin (argipressin) in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vasopressin (argipressin) products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Empesin
  • Belgium · Reverpleg
  • Bulgaria · Емпресин
  • Czechia · Embesin
  • Germany · Argipressin Farmak, Empressin
  • Denmark · Empressin
  • Estonia · Empesin
  • Spain · Empressin
  • Finland · Empressin
  • France · Reverpleg
  • United Kingdom (Northern Ireland) · Argipressin Aop, Argipressin Mercury Pharmaceuticals
  • Greece · Empressin
  • Croatia · Empressin
  • Hungary · Embesyn
  • Ireland · Embesin
  • Italy · Empressin
  • Lithuania · Empesin
  • Luxembourg · Reverpleg
  • Latvia · Empesin
  • Netherlands · Empressine
  • Norway · Empressin
  • Portugal · Empressin
  • Romania · Reverpleg
  • Sweden · Empressin
  • Slovenia · Empesin
  • Slovakia · Embesin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ed4a9521-6946-4c02-9804-c1117aa66dda
GET /v1/drugs/ed4a9521-6946-4c02-9804-c1117aa66dda?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "20 IU/ml",
  "packaging": "05907637916146 ¦ Lz ¦ 160263\n10 amp. 1 ml\n05907637916153 ¦ Lz ¦ 160264\n10 amp. 2 ml",
  "substance": "Argipressinum 20 IU/ml",
  "common_name": "Argipressinum",
  "pl_product_id": "100469780",
  "pozwolenie_nr": "28842",
  "auth_procedure": "DCP",
  "authorisation_validity": "2030-01-29"
}
API referenceMCP serverPlans

See everything about vasopressin (argipressin).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console